BMS Teams Up with AstraZeneca to Buy Amylin for US$7 B
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 10 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1764 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Bristol-Myers Squibb has succeeded in its pursuit of Amylin Pharmaceuticals by agreeing to acquire the company in a deal valued at approximately US$7 B, including US$1.7 B towards the settlement of Amylin’s net debt and a contractual payment obligation to Eli Lilly. In an interesting twist, upon closing of the transaction AstraZeneca will pay approximately US$3.4 B in cash in order to become a development and commercialisation partner for Amylin’s product portfolio with equal sharing of profits and losses.
Copyright: © IQVIA 2018
RSS